Head-to-head · free

uniQure vs Rocket Pharmaceuticals, Inc.

QURE vs RCKT — return on capital, cash generation, margins and balance sheet side by side.

QURE

3 / 3

measures where QURE leads

RCKT

0 / 3

measures where RCKT leads

A simple count of which company scores better on each measure — not a recommendation to buy or sell.

MeasureQURE · FY2025RCKT · FY2025
Revenue—$0
Net income(199.0M)(223.1M)
Revenue growth (yearly, multi-year)-47.8%—
Free cash flow(178.4M)(190.5M)
Free cash flow margin——
Net cash / (debt)——
ROIC——
Return on equity—-60.3%
Gross margin89.5%—
Operating margin-1166.8%—
Net debt / EBITDA0.18x0.35x

Figures are as reported by each company; latest fiscal year shown.

Where uniQure's cash went (FY2025)

Capital spending
$439000
Buybacks
—
Dividends
—
Acquisitions
—
Net debt issued / (repaid)
—
Full QURE profile →

Where Rocket Pharmaceuticals, Inc.'s cash went (FY2025)

Capital spending
$440000
Buybacks
—
Dividends
—
Acquisitions
—
Net debt issued / (repaid)
—
Full RCKT profile →

Ask which business is stronger

"Which one reinvests at higher returns?" "Who carries more risk in its filings?" Get answers drawn straight from both companies' filings.

Compare them free

More comparisons